Ketamine for Anxiety: What the Emerging Research Shows

# Ketamine for Anxiety: What the Emerging Research Shows

When people talk about ketamine therapy, they almost always mean ketamine for depression. The depression research is more mature, the clinical trials are larger, and the FDA-approved version (Spravato) was approved specifically for treatment-resistant depression.

But anxiety and depression are deeply intertwined — and researchers are increasingly asking whether ketamine's rapid-acting mechanism could help anxiety disorders on their own.

Why anxiety is harder to study

Depression has a dominant assessment tool — the Hamilton Depression Rating Scale (HAM-D) or the Montgomery-Åsberg Depression Rating Scale (MADRS). Most ketamine studies measure the same thing the same way.

Anxiety is more fragmented. Generalized anxiety disorder, social anxiety disorder, panic disorder, OCD, and PTSD all fall under the anxiety umbrella but involve different brain circuits, different symptoms, and potentially different responses to treatment. Studying "ketamine for anxiety" requires specifying which anxiety — and that splits already-small study populations into even smaller groups.

What the data shows so far

Generalized anxiety disorder (GAD): A small 2017 study by [Glue and colleagues in Journal of Psychopharmacology](https://pubmed.ncbi.nlm.nih.gov/28441895/) gave ascending single doses of subcutaneous ketamine (0.25, 0.5, 1 mg/kg) at weekly intervals to 12 patients with treatment-refractory generalized anxiety disorder and/or social anxiety disorder. Patients reported reduced anxiety within one hour of dosing, and the effect persisted for up to seven days. Ten of 12 patients met treatment-response criteria at 0.5-1 mg/kg. The trial was small and uncontrolled, but the signal was clear.

Social anxiety disorder: The same study included patients with social anxiety, and the results were similarly positive. Subsequent case series have reported that socially anxious patients sometimes experience the most dramatic improvements — though this observation hasn't been validated in large trials. [A randomized, placebo-controlled crossover trial in 18 adults with SAD found that a single 0.5 mg/kg IV ketamine infusion significantly reduced Liebowitz Social Anxiety Scale scores compared to placebo](https://pubmed.ncbi.nlm.nih.gov/28849779/), with response sustained over two weeks of follow-up.

PTSD: This is where the evidence is strongest. In a [2021 randomized controlled trial by Feder and colleagues in American Journal of Psychiatry](https://pubmed.ncbi.nlm.nih.gov/33397139/), 30 adults with chronic PTSD received six infusions of 0.5 mg/kg ketamine or midazolam (psychoactive placebo) over two consecutive weeks. The ketamine group showed significantly greater improvement on the CAPS-5 PTSD severity scale from baseline to week 2, with 67% of ketamine recipients meeting response criteria versus 20% on midazolam. Among responders, median time to loss of response was 27.5 days after the two-week infusion course — meaningful relief, but not lasting.

OCD: The OCD data is intriguing but very early. A few small studies have shown rapid but temporary reduction in obsessive-compulsive symptoms. The transient nature of the response is a concern — it suggests ketamine may interrupt OCD circuits temporarily without producing lasting change. [A proof-of-concept randomized crossover trial of 15 unmedicated OCD adults found that a single 0.5 mg/kg IV infusion produced rapid reduction in obsessions, with 50% of ketamine recipients meeting response criteria at one week versus 0% on placebo](https://pubmed.ncbi.nlm.nih.gov/23783065/).

The glutamate connection

Ketamine's mechanism in anxiety may overlap with its antidepressant mechanism — both likely involve rapid changes in glutamate signaling and downstream effects on neuroplasticity. The amygdala (fear center) and prefrontal cortex (regulation center) communicate through glutamate pathways, and ketamine appears to modulate this communication.

Some researchers hypothesize that ketamine's anti-anxiety effects may actually be faster and more robust than its antidepressant effects, because the fear circuits are more directly influenced by glutamate modulation. This is speculative but biologically plausible.

What's missing

No large, multi-site randomized controlled trial has been published for ketamine in any specific anxiety disorder (other than PTSD). The studies that exist are small, often open-label, and frequently don't separate anxiety improvement from depression improvement — since many participants have both.

This is a real gap. Clinicians who use ketamine off-label report seeing anxiety respond, but the evidence base hasn't caught up to clinical experience.

Why this matters going forward

Anxiety disorders are among the most common mental health conditions — affecting roughly 40 million adults in the US. First-line treatments (SSRIs, SNRIs, buspirone, therapy) work for many people but leave a significant minority without adequate relief. Benzodiazepines work quickly but carry addiction risk and cognitive side effects.

A treatment that could reduce anxiety rapidly without the dependency risk of benzodiazepines would be genuinely significant. Whether ketamine fills that role — or inspires the next generation of drugs that do — is one of the more important open questions in psychiatric research.

---

This article is for educational purposes. Dr. Kim does not currently offer ketamine therapy but monitors this research as part of staying current on treatment-resistant mental health conditions. For help with anxiety, [start here](/intake/mental-health).